

The Manager
Company Announcements Office
ASX Limited

LBT BEGINS CLINICAL TRIALS OF APAS® TECHNOLOGY

19 September 2014, Melbourne: Medical technology company LBT Innovations Limited (ASX: LBT) has this week launched the first two of three clinical trials to demonstrate the efficacy of its Automated Plate Assessment System (APAS), at the laboratories of Healthscope Pathology in Melbourne and Adelaide. The pioneering automated culture-plate analysis and reporting system is being tested on urine samples to demonstrate its accuracy and efficiency in screening culture plates for pathogens linked to urinary tract infections.

Following the two Australian trials, APAS will be subjected to a third clinical trial at a leading laboratory in the United States, due to begin in late 2014. This final trial will precede a 510(k) *de novo* submission to the US Food and Drug Administration (FDA), which is required before a medical device can be distributed commercially in the US market. LBT has been in discussions with the FDA to ensure that its clinical trials are structured to meet the specific FDA requirements.

Earlier this year, the pathogen screening capabilities of APAS were presented in two comparative studies to the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and the annual meeting of the Australian Society for Microbiology. The two studies showed the APAS prototype matching the findings of teams of experienced microbiologists, without missing a single potential pathogen.

APAS is currently being incorporated into automated laboratory solutions by the Swiss instrumentation company, Hettich AG Switzerland, which has entered into a 50:50 joint venture with LBT to commercialise the technology. APAS is being integrated into a novel bench top culture plate reader and also with Hettich's auto-incubator.

The Hettich-LBT joint venture company, Clever Culture Systems AG Switzerland, has also filed five patent applications in Europe to support various components of the APAS technology.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. LBT also has a third product in development, Woundvue™, a proposed automation solution to assist in the management of chronic wounds.

LBT has an exclusive global licence agreement with French diagnostics company bioMérieux to manufacture and market PREVI® Isola. LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories in around the world. LBT's APAS® technology is nearing market. Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au